B9061

Bicalutamide (CDX)

≥98% (HPLC), powder

• Synonyme(s) : Casodex, Cosudex, N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
• Formule empirique (notation de Hill): C₁₈H₁₄F₄N₂O₄S
• Numéro CAS: 90357-06-5
• Poids moléculaire : 430.37
• Numéro MDL: MFCD00869971
• Code UNSPSC : 12352200
• ID de substance PubChem : 329773312
• Nomenclature NACRES : NA.77

Propriétés

• Niveau de qualité: 100
• Essai: ≥98% (HPLC)
• Forme: powder
• Conditions de stockage: desiccated; protect from light
• Solubilité: DMSO: >5 mg/mL; H₂O: insoluble
• Auteur: AstraZeneca
• Chaîne SMILES: CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F
• InChI: 1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
• Clé InChI: LKJPYSCBVHEWIU-UHFFFAOYSA-N
• Informations sur le gène: human ... AR(367)

Description

Application

Bicalutamide (CDX) has been used as an androgen receptor (AR) antagonist in prostate,[1] bladder cancer cell lines[2] and human fetal skeletal muscle cells.[3] It has also been used as a supplement in RPMI 1640 for culturing androgen-independent LNCaP (LNCaP-AI) cell line.[4]

Actions biochimiques/physiologiques

Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) antagonist and a pure antiandrogen. It acts via balancing histone acetylation/deacetylation and recruitment of coregulators. Bicalutamide (CDX) abolishes androgen-mediated expression. For example, MMP13 upregulation in prostate cancer, PLZF (promyelocytic leukemia zinc finger protein), and GADD45γ (growth arrest and DNA damage inducible, gamma). Bicalutamide (CDX) is inhibited by non-genomic, transcription-independent stimulation of PI3K/AKT phosphorylation by androgens.

Caractéristiques et avantages

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• Pictogrammes: GHS08,GHS09
• Mention d'avertissement: Danger
• Mentions de danger: H351,H360FD,H410
• Conseils de prudence: P202 - P273 - P280 - P308 + P313 - P391 - P405
• Classification des risques: Aquatic Chronic 1 - Carc. 2 - Repr. 1B
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• Équipement de protection individuelle: dust mask type N95 (US), Eyeshields, Gloves